Cargando…

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age

Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available. The objective of this study was to provide an up-to-date cost-utility assessment of palivizumab vers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keary, Ian P., Ravasio, Roberto, Fullarton, John R., Manzoni, Paolo, Lanari, Marcello, Paes, Bosco A., Carbonell-Estrany, Xavier, Baraldi, Eugenio, Tarride, Jean-Éric, Rodgers-Gray, Barry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414677/ https://www.ncbi.nlm.nih.gov/pubmed/37561741 http://dx.doi.org/10.1371/journal.pone.0289828

Ejemplares similares

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
por: Lanari, M., et al.
Publicado: (2020)

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study
por: Simões, Eric AF, et al.
Publicado: (2008)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
por: Simões, Eric A. F., et al.
Publicado: (2018)

The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood
por: Fauroux, Brigitte, et al.
Publicado: (2017)

Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
por: Bont, Louis, et al.
Publicado: (2016)

Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
por: Paes, Bosco, et al.
Publicado: (2013)

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases
por: Manzoni, Paolo, et al.
Publicado: (2017)

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
por: Resch, B., et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease
por: Paes, Bosco, et al.
Publicado: (2016)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease
por: Checchia, Paul A., et al.
Publicado: (2017)

Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS])
por: Carbonell‐Estrany, Xavier, et al.
Publicado: (2018)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease
por: Figueras-Aloy, Josep, et al.
Publicado: (2016)

Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation
por: Goldstein, Mitchell, et al.
Publicado: (2021)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
por: Mohammed, Mohammed Hassan A., et al.
Publicado: (2021)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis
por: Krilov, Leonard R, et al.
Publicado: (2014)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
por: Elhalik, M., et al.
Publicado: (2019)

Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
por: Choi, Yoonyoung, et al.
Publicado: (2021)

Evaluation of a Novel Web-Based Prior Approval Application for Palivizumab Prophylaxis of Respiratory Syncytial Virus in a State Medicaid Program
por: Lundeen, Kristin, et al.
Publicado: (2013)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u4ea7gbsvipt27kliamrl4pv7c